- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Therapy of Melanoma - September 2002
National Cancer Institute®
Last Modified: September 1, 2002
- Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
- Surgical techniques of melanoma and sentinel node biopsy.
- Mohs micrographically controlled surgery and the treatment of malignant melanoma.
- European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma.
- Adjuvant therapy for patients with high-risk malignant melanoma.
- Isolated limb perfusion in locally advanced cutaneous melanoma.
- Interleukin-2 and histamine dihydrochloride in metastatic melanoma.
- Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients.
- Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human
- Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II
- Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb
- Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
- Primary malignant mucosal melanoma of the head and neck region: pooled analysis of 60 published cases from India and review of literature.
- [Malignant skin melanoma]
- A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft
- The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro.
- Therapy of melanoma with allogeneic melanoma lysates alone or with interferon-alfa.
- Nevus, redux.
- Interview with professor Bin Kroon.
- Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based
- Phase II trial of carbetimer in metastatic melanoma.
- Value of neck dissection in the treatment of patients with intermediate-thickness cutaneous malignant melanoma of the head and
- Considerations in the surgical treatment of malignant melanoma.
- The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival.
- Sentinel node biopsy site used as full thickness skin graft donor for cutaneous melanoma.
- Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory
- How does interferon work? Does it even matter?
- Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells.
- Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
- Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer -- a pilot study.
- [The shadow rule and appropriate sun behavior]
- [Role of sentinel node biopsy in the management of melanoma]
- [Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials]
- [Comment on the contribution by A. Hauschild et al.: "Safety margins in excision of primary malignant melanoma"]
- Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma
- Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the
- Relative biological effectiveness of boron ions on human melanoma cells.
- Malignant melanoma.
- Vaccination for malignant melanoma: recent developments.
- Royal College of Radiologists Annual Undergraduate Essay Prize. Melanoma: the new smallpox? Can vaccines be used to treat melanoma?
- Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping
- [What is the role of sunscreens in the prevention of melanoma?]
- [Dermatology, melanoma]
- [Recommendations for the management of melanoma]
- Adjuvant irradiation for axillary metastases from malignant melanoma.
- A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest
- Current concepts in the management of patients with melanoma.
- A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with
- Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic
Table of Contents
1
UI - 11417749
AU - Dreau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
TI -
Angiogenic and immune parameters during recombinant interferon-alpha2b
adjuvant treatment in patients with melanoma.
SO - Oncol Res 2000;12(5):241-51
AD - Department of General Surgery Research, Carolinas Medical Center,
Charlotte, NC 28203, USA. ddreau@carolinas.org
As an adjuvant therapy for patients with high risk of recurrent
melanoma, high-dose interferon (IFN)-alpha2b therapy has been shown to
have some efficacy. We examined 22 patients with resected melanoma who
were treated with repeated injections of recombinant IFN-alpha2b during
the treatment. Both angiogenic and immune parameters were measured.
White blood cells (WBCs) and lymphocyte numbers, lymphocyte
subpopulations, serum concentrations of IFN-alpha and anti-IFN-alpha
antibodies, and the serum vascular endothelial growth factor (VEGF),
interleukin (IL)-8, and basis fibroblast growth factor (bFGF)
concentrations were determined over time in resected, recurrence-free
patients with American Joint Committee on Cancer (AJCC) stage III
melanoma with one or less (LN+ < or = 1, n = 7) or more than one (LN+ >
1, n = 8) lymph nodes involved, and AJCC stage IV resected disease (n =
7). Follow-up and recurrence-free intervals were longer in stage III
(LN+ < or = 1) patients compared with stage IV patients (P < 0.05). The
number of WBCs and lymphocytes decreased during the treatment for all
patient groups (P < 0.001). In addition, percentages of CD8 and CD20
were higher in stage IV patients than in stage III (LN+ > 1) and stage
III (LN+ < or = 1) patients at the beginning of therapy (P < 0.05). A
significant increase in the percentage of CD20+ cells, mostly B
lymphocytes, was observed in the stage III (LN+ > 1) and stage III (LN+
< or = 1) patients over time but not in stage IV patients (P < 0.001).
Low IL-8 and bFGF concentrations at the beginning of therapy were
associated with significantly longer recurrence-free survival (P <
0.05). These results warrant a larger trial to determine if the
differences observed in patients before treatment can provide prognostic
markers in patients receiving IFN-alpha2b therapy.
2
UI - 12170435
AU - Testori A; Mozzillo N
TI -
Surgical techniques of melanoma and sentinel node biopsy.
SO - Semin Oncol 2002 Aug;29(4):328-35
AD - Melanoma Unit, European Institute of Oncology, Milan, Italy.
The adequacy of surgical treatment of melanoma patients is the most
important milestone in the natural history of the disease, once the
diagnosis has been confirmed. Surgery plays a fundamental role in the
initial stages of the disease, ie, to remove the primary lesion and to
excise accurately the locoregional metastases. On the contrary, the
impact of a surgical indication to treat distant metastases has never
been confirmed in a prospective study; thus, there are no standard
guidelines and it represents a decision to be discussed with each
individual patient. Copyright 2002, Elsevier Science (USA). All rights
reserved.
3
UI - 12170436
AU - Nagi C; O'Grady TC; Izadpanah A
TI -
Mohs micrographically controlled surgery and the treatment of malignant
melanoma.
SO - Semin Oncol 2002 Aug;29(4):336-40
AD - Division of Dermatology, University of California, San Diego, School of
Medicine, San Diego, CA, USA.
Mohs micrographic surgery is a technique that offers surgeons and
pathologists a means to examine the entire surgical margins of excised
cutaneous malignancies in a more complete manner than conventional
methods. Initially developed to treat nonmelanoma skin cancers, its use
has been expanded to include histologic margin evaluation for treatment
of malignant melanoma. Clinical studies demonstrate equivalent or better
5-year survival rates with Mohs surgery compared to conventional wide
local excision. For surgical treatment of melanoma, it offers unique
advantages for lesions requiring tissue conservation and accurate margin
determination, particularly in anatomic sites where cosmetic and
functional concerns are of importance (head and neck, hands, and feet),
and for large or ill-defined lesions such as lentigo maligna or lentigo
maligna melanoma. Copyright 2002, Elsevier Science (USA). All rights
reserved.
4
UI - 12170441
AU - Eggermont AM; Gore M
TI -
European approach to adjuvant treatment of intermediate- and high-risk
malignant melanoma.
SO - Semin Oncol 2002 Aug;29(4):382-8
AD - Department of Surgical Oncology, Erasmus University Medical
Center-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Adjuvant therapies for patients with melanoma at high risk of relapse
whether local, such as excision margins, elective regional lymph node
dissection (ELND), and prophylactic isolated limb perfusion (ILP), or
systemic, such as chemotherapy, immunotherapy, immunochemotherapy, or
vaccination therapy, have little or no impact on survival when evaluated
in randomized trials. The European approach to the treatment of each
stage of malignant melanoma is characterized by thoughtful caution with
particular attention being paid to the avoidance of unwarranted
mutilation or toxicity because phase 3 studies have failed to
demonstrate unequivocal benefits for a more aggressive approach. In
Europe, there is no standard adjuvant systemic therapy; high-dose
interferon (IFN) is used sporadically in individual patients by some
physicians, but there is little enthusiasm for adopting this regimen as
the standard of care because of its high toxicity profile and the lack
of a clear beneficial impact on long-term survival. Less toxic
lower-dose maintenance IFN regimens, antiangiogenic agents, and vaccine
therapies are currently being explored. Copyright 2002, Elsevier Science
(USA). All rights reserved.
5
UI - 12170442
AU - McClay EF
TI -
Adjuvant therapy for patients with high-risk malignant melanoma.
SO - Semin Oncol 2002 Aug;29(4):389-99
AD - San Diego Cancer Research Institute, and San Diego Melanoma Research
Program, Vista, CA, USA.
The role of adjuvant therapy in the treatment of patients with high-risk
malignant melanoma remains an area of intense investigation. The initial
enthusiasm for high-dose interferon has been tempered by the results of
more recent studies that allow for conflicting interpretations. Vaccine
therapy trials have failed to clearly demonstrate a survival benefit,
although several trials are currently ongoing. Recent studies of the
role of chemotherapy suggest there may be combinations that have a
survival benefit which deserve further study. This article will address
patient selection and staging workup, and review options for treatment.
Copyright 2002, Elsevier Science (USA). All rights reserved.
6
UI - 12170443
AU - Rossi CR; Foletto M; Pilati P; Mocellin S; Lise M
TI -
Isolated limb perfusion in locally advanced cutaneous melanoma.
SO - Semin Oncol 2002 Aug;29(4):400-9
AD - Department of Surgical and Oncological Sciences Clinica Chirurgica II,
University of Padova, Padova, Italy.
Isolated limb perfusion (ILP) is a well-established locoregional
procedure to deliver high doses of cytostatics to an extremity with
multiple in-transit lesions from cutaneous melanoma, with minimal
systemic and mild local toxicity. This approach is quite sophisticated
and requires accurate monitoring of systemic leakage and of the
temperature of the affected limb in order to avoid major systemic and
local side effects. Mephalan (L-PAM) is considered the reference drug,
although complete responses are reported in only about 50% of patients.
Since the early 1990s, tumor necrosis factor-alpha (TNF-alpha) was
administered with melphalan in ILP aiming to improve the therapeutic
index of this procedure. However, despite the impressive results
reported, its role still remains controversial, seemingly confined to
large tumor bulk. Fotemustine ILP was proposed as a less toxic
alternative to L-PAM, after the results of a pilot experience claiming
similar response rates with less local toxicity. A formal phase 1-2
study is now underway to confirm these findings. More straightforward
procedures, such as isolated limb infusion, are appealing, as they seem
capable of achieving good response rates, are easily repeatable, and are
less costly. Larger series are required to validate such results. As
potential agents to be delivered through ILP, new vasoactive drugs and
agents with new mechanisms of action that interplay with chemotherapy,
as well as virus-mediated gene therapy, are being developed. Copyright
2002, Elsevier Science (USA). All rights reserved.
7
UI - 12177116
AU - Agarwala SS; Hellstrand K; Naredi P
TI -
Interleukin-2 and histamine dihydrochloride in metastatic melanoma.
SO - J Clin Oncol 2002 Aug 15;20(16):3558-9
8
UI - 12177119
AU - Koduri J; Baumann MA
TI -
Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and
interferon alfa-2b in advanced melanoma outpatients.
SO - J Clin Oncol 2002 Aug 15;20(16):3560; discussion 3560-1
9
UI - 12086721
AU - Wasan EK; Waterhouse D; Sivak O; Bally MB; Klasa RJ; Wasan KM
TI -
Plasma protein binding, lipoprotein distribution and uptake of free and
lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human
melanoma cells.
SO - Int J Pharm 2002 Jul 8;241(1):57-64
AD - Faculty of Medicine, The University of British Columbia, Vancouver, BC,
Canada V6T 1Z3. kwasan@interchange.ubc.ca
The objectives of this study were to determine the protein binding and
lipoprotein distribution of G3139 and G3139 lipoplexes following
incubation in human plasma, assess complement activation of, and the
effect of pre-incubation of G3139 and G3139 lipoplexes in human plasma
on in vitro cellular uptake of G3139. Effect of concentration and time
on incorporation of free and lipid associated (lipoplexes) [3H]Bcl-2 AO
(25-600 ng/ml) into normolipidemic human plasma lipoproteins was
determined by density gradient ultracentrifugation after incubation at
37 degrees C for 5, 30, 60 and 120 min. Protein binding in the
lipoprotein deficient fractions (LPDP) was determined by equilibrium
dialysis. Complement interaction was determined by ELISA after exposure
of human plasma to AO+/- liposomes prepared in serial dilution. In vitro
uptake of G3139 and G3139 lipoplexes into human melanoma cells was
assessed qualitatively by fluorescence microscopy after 4-h exposure to
G3139 (free or as lipoplexes) with or without pre-incubation of G3139 in
normal human plasma. Analysis of Bcl-2 AO-lipoprotein interaction over
time and concentration indicated no significant movement of the compound
within the different lipoprotein and LPDP fractions. Majority of drug
was recovered within LPDP fraction, and more than 85% of drug recovered
within LPDP fraction was protein bound. No significant activation of
complement was noted for either free AO or lipoplexes. Pre-incubation of
free AO or AO-lipoplexes in human plasma resulted in a greater cellular
uptake of AO-lipoplexes compared with plasma free controls. These
findings suggest that the majority of [3H]Bcl-2 AO is plasma protein
bound with little lipoprotein association and no significant movement
between different lipoprotein and LPDP fractions. Plasma protein binding
other than lipoprotein binding may be responsible for the difference in
cellular uptake of free AO vs. cationic lipoplexes.
10
UI - 12149297
AU - DiFronzo LA; Gupta RK; Essner R; Foshag LJ; O'Day SJ; Wanek LA; Stern
TI -
SL; Morton DL
Enhanced humoral immune response correlates with improved disease-free
and overall survival in American Joint Committee on Cancer stage II
melanoma patients receiving adjuvant polyvalent vaccine.
SO - J Clin Oncol 2002 Aug 1;20(15):3242-8
AD - Sonya Valley Ghidossi Vaccine Laboratory, Roy E. Coats Research
Laboratories, John Wayne Cancer Institute at Saint John's Health Center,
2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
PURPOSE: Although the improved overall survival (OS) of patients who
receive Canvaxin (CancerVax Corp, Carlsbad, CA) polyvalent vaccine (PV)
immunotherapy for metastatic melanoma has been correlated with cellular
and humoral immune responses, the mechanisms of vaccine immunotherapy
for early-stage melanoma are unclear. Specific immune responses to
tumor-associated antigens might correlate with disease-free survival
(DFS) and OS in patients receiving adjuvant PV therapy for primary
melanoma. PATIENTS AND METHODS: Eighty-three patients received PV plus
bacille Calmette-Guerin after wide excision of American Joint Committee
on Cancer stage II melanoma. Humoral and cellular responses during the
first 12 weeks of adjuvant immunotherapy were assessed by serum antibody
titers to a tumor-associated 90-kd glycoprotein antigen (TA90) expressed
by PV, and by delayed-type hypersensitivity (DTH) skin testing with PV
(PV-DTH). RESULTS: At a median follow-up period of 46.6 months (range,
10.7 to 93.6 months), an increased PV-DTH response seemed to be
associated with improved 5-year DFS (54% v 20%) and 5-year OS (75% v
60%), but the correlations were not statistically significant. Anti-TA90
immunoglobulin (Ig) M levels > or = 1:800 were significantly correlated
with improved 5-year DFS and improved 5-year OS, and multivariate
analysis identified anti-TA90 IgM as an independent prognostic factor
for OS and DFS. CONCLUSION: These findings suggest that an increased IgM
response in patients receiving PV therapy for stage II melanoma is
associated with decreased recurrence and improved survival.
11
UI - 12149303
AU - Stein U; Jurchott K; Schlafke M; Hohenberger P
TI -
Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined
sequentially before, during, and after hyperthermic isolated limb
perfusion of soft tissue sarcoma and melanoma patients.
SO - J Clin Oncol 2002 Aug 1;20(15):3282-92
AD - Division of Surgery and Surgical Oncology, Charite, Humboldt University,
Campus Berlin-Buch, Robert Rossle Hospital and Tumor Institute,
Robert-Rossle-Strasse 10, 13092 Berlin, Germany. ustein@mdc-berlin.de
PURPOSE: Isolated, hyperthermic limb perfusion (ILP) with recombinant
human tumor necrosis factor alpha and melphalan is a highly effective
treatment for advanced soft tissue sarcoma (STS) and locoregional
metastatic malignant melanoma. Multidrug resistance (MDR)-associated
genes are known to be inducible by heat and drugs; expression levels of
the major vault protein (MVP), MDR1, and MDR-associated protein 1 (MRP1)
were determined sequentially before, during, and after ILP of patients.
PATIENTS AND METHODS: Twenty-one STS or malignant melanoma patients were
treated by ILP. Tumor tissue temperatures were recorded continuously and
ranged from 33.4 degrees C initially to peak values of 40.4 degrees C
during ILP. Serial true-cut biopsy specimens from tumor tissues were
routinely microdissected. Expression analyses for MDR genes were
performed by real-time reverse transcriptase polymerase chain reaction
and immunohistochemistry. RESULTS: In 83% of the patients, MVP
expression was induced during hyperthermic ILP. MVP-mRNA inductions
often paralleled the increase in temperature during ILP. Increased MVP
protein expressions either were observed simultaneously with the
MVP-mRNA induction or were delayed until after the induction at the
transcriptional level. Inductions of MDR1 and MRP1 were observed in only
13% and 27% of the specimens analyzed. Temperatures and drugs applied
preferentially led to an induction of MVP and were not sufficient to
induce MDR1 and MRP1 in the majority of tumors. CONCLUSION: This study
is the first to analyze the expression of MDR-associated genes
sequentially during ILP of patients and demonstrates that treatment
might lead to increased levels of MVP, whereas enhanced levels of MDR1
and MRP1 remain rare events.
12
UI - 12039921
AU - Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO;
TI -
Williams LJ; Quinn CJ; Houghton AN
Temozolomide plus thalidomide in patients with advanced melanoma:
results of a dose-finding trial.
SO - J Clin Oncol 2002 Jun 1;20(11):2610-5
AD - Departments of Medicine, Epidemiology and Biostatistics, and Radiology,
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
hwuw@mskcc.org
PURPOSE: To establish a safe and tolerated regimen of an oral cytotoxic
agent, temozolomide, and a cytostatic agent, thalidomide, in patients
with unresectable stage III or IV malignant melanoma. PATIENTS AND
METHODS: Patients with unresectable stage III or IV melanoma without
brain metastases were entered successively onto four treatment cohorts:
level 1, temozolomide 50 mg/m(2)/d for 6 weeks followed by a 4-week
break; levels 2, 3, and 4, temozolomide 75 mg/m(2)/d for 6 weeks
followed, respectively, by breaks of 4, 3, and 2 weeks. Thalidomide was
started at 200 mg/d, and escalated to a maximum dose of 400 mg/d. Safety
was assessed at weeks 2 and 4 and every 4 weeks thereafter; tumor
response was evaluated every 8 to 10 weeks. RESULTS: Twelve patients
were enrolled, three on each cohort. Therapy was generally well
tolerated on all of the treatment schedules. Thalidomide at a dose of
400 mg/d was well tolerated in patients younger than 70, and 200 mg/d
was well tolerated in older patients. The most common adverse events
were grade 2 or 3 constipation and neuropathy, which were attributed to
thalidomide. Five major responses (one complete, four partial) were
documented, all at dose levels 2 to 4. Three of the five responding
patients were in the over-70 age group. The median duration of response
was 6 months (range, 4 to 17+ months), and the median overall survival
was 12.3 months (range, 4 to 19+ months). CONCLUSION: The combination of
temozolomide and thalidomide was well tolerated and had antitumor
activity in patients with advanced melanoma, including elderly patients
over 70 years old.
13
UI - 11917203
AU - Pandey M; Mathew A; Iype EM; Sebastian P; Abraham EK; Nair KM
TI -
Primary malignant mucosal melanoma of the head and neck region: pooled
analysis of 60 published cases from India and review of literature.
SO - Eur J Cancer Prev 2002 Feb;11(1):3-10
AD - Department of Surgical Oncology, Regional Cencer Centre, Medical College
PO, Trivandrum, Kerala, 695 011, India. manojpandey@vsnl.com
Malignant melanoma arising in the head and neck mucosa is a rare entity
with incidence ranging from 2% to 10%. Because of the lack of data, the
biological behaviour of these lesions still remains unpredictable and
outcome dismal. We carried out a literature review for cases of mucosal
melanoma of the head and neck reported from India and performed a pooled
analysis on the available data. A total of 60 cases of head and neck
melanomas were reported, of which 46 were in men. Palate and alveolus
were the commonest sites. A total of 29 (48.3%) patients had regional
node metastasis at presentation while five (12%) had distant metastasis.
Three-year overall survival of 27.7% was observed. However, the
disease-free survival rates at 3, 5 and 6 years were 39.4%, 39.4% and
13.1%, respectively. Metastasis at presentation and use of adjuvant
radiotherapy were found to be the only significant predictors of
survival. Malignant mucosal melanoma has aggressive biological behaviour
and poor outcome. Radical surgery and adjuvant radiotherapy may provide
a better local control and may help in improving survival.
14
UI - 12082854
AU - Drzewiecki KT; von der Maase H
TI -
[Malignant skin melanoma]
SO - Ugeskr Laeger 2002 Jun 3;164(23):3031-5
AD - Plastik- og brandsarsafdelingen, H:S Rigshospitalet, DK-2100 Kobenhavn
o.
15
UI - 12072074
AU - Farshad A; Burg G; Panizzon R; Dummer R
TI -
A retrospective study of 150 patients with lentigo maligna and lentigo
maligna melanoma and the efficacy of radiotherapy using Grenz or soft
X-rays.
SO - Br J Dermatol 2002 Jun;146(6):1042-6
AD - Department of Dermatology, University Hospital Zurich, Gloriastrasse 31,
CH-8091 Zurich, Switzerland.
BACKGROUND: Lentigo maligna (LM) and lentigo maligna melanoma (LMM) are
the most common melanocytic neoplasms on sun-exposed skin of elderly
patients. OBJECTIVES: To perform a retrospective study of 150 patients
with LM and LMM treated with radiotherapy using Grenz or soft X-rays.
METHODS: The information recorded and analysed included gender, age,
diagnosis, size of the lesion, localization, X-ray treatment, recurrence
rate, other skin malignancies and non-dermatological neoplasms. RESULTS:
The 150 patients comprised 78 women and 72 men (mean age 70 years).
Ninety-three patients had LM, 54 had LMM and three had both neoplasms.
Ninety per cent of lesions were located on the face. Treatment was with
Grenz rays in 96 patients with LM and 11 with LMM (70%) and with soft
X-rays in 46 patients with LMM (30%). Three patients were treated using
both modalities. One hundred and one patients were followed up for at
least 2 years after radiotherapy (mean 8 years). The mean time to
recurrence was 45.6 months, and the recurrence rate was 7% (seven of
101). Other skin malignancies were observed in 65 of 150 patients,
including basal cell carcinoma in 23 (35%) and actinic keratosis in 20
(31%). Four patients developed internal cancers. CONCLUSIONS: The study
showed that radiotherapy of LM and LMM was curative. In particular,
radiotherapy proved to be an excellent treatment for elderly patients.
Owing to the high incidence of other skin cancers, LM patients need
careful follow-up.
16
UI - 12177810
AU - Riebeling C; Forsea AM; Raisova M; Orfanos CE; Geilen CC
TI -
The bisphosphonate pamidronate induces apoptosis in human melanoma cells
in vitro.
SO - Br J Cancer 2002 Jul 29;87(3):366-71
AD - Department of Dermatology, University Medical Center Benjamin Franklin,
The Free University of Berlin, Fabeckstr. 60-62, 14 195-Berlin, Germany.
Pamidronate belongs to the class of nitrogen-containing bisphosphonates
that are potent inhibitors of bone resorption frequently used for the
treatment of osteoporosis and cancer-induced osteolysis. The inhibition
of osteoclasts' growth has been suggested as the main mechanism of the
inhibitory effect of pamidronate on bone metastases. Recent findings
indicated that bisphosphonates also have a direct apoptotic effect on
other types of tumour cells. Nitrogen-containing bisphosphonates were
shown to inhibit farnesyl diphosphate synthase, thus blocking the
synthesis of higher isoprenoids. By this mechanism they inactivate
monomeric G-proteins of the Ras and Rho families for which prenylation
is a functional requirement. On the background of the known key role of
G-proteins in tumorigenesis, we investigated a possible beneficial use
of pamidronate in the treatment of malignant melanoma. Our results
indicate that pamidronate inhibits the cell growth and induces apoptosis
in human melanoma cells in vitro. Susceptibility to pamidronate did not
correlate to CD95 ligand sensitivity or p53 mutational status.
Furthermore it is interesting to note that overexpression of bcl-2 did
not abolish pamidronate-induced apoptosis. These data suggests that
pamidronate has a direct anti-tumour effect on malignant melanoma cells,
independently of the Bax/Bcl-2 level. Copyright 2002 Cancer Research UK
17
UI - 12197233
AU - Mitchell MS; Darrah D; Stevenson L
TI -
Therapy of melanoma with allogeneic melanoma lysates alone or with
interferon-alfa.
SO - Cancer Invest 2002;20(5-6):759-68
AD - Hudson-Webber Cancer Research Center, Karmanos Cancer Institute, 110
East Warren Avenue, Suite 740, Detroit, MI 48201, USA.
18
UI - 11801787
AU - LeBoit PE
TI -
Nevus, redux.
SO - Am J Dermatopathol 2001 Oct;23(5):491-3
AD - Department of Pathology, University of California, San Francisco,
California 94115, USA. philipl@itsa.ucsf.edu
19
UI - 12199197
AU - Kroon B
TI -
Interview with professor Bin Kroon.
SO - Eur J Cancer 2002 Jul;38(11):1425
20
UI - 12110497
AU - Keilholz U; Martus P; Punt CJ; Kruit W; Mooser G; Schadendorf D; Lienard
TI -
D; Dummer R; Koller J; Voit C; Eggermont AM
Prognostic factors for survival and factors associated with long-term
remission in patients with advanced melanoma receiving cytokine-based
treatments: second analysis of a randomised EORTC Melanoma Group trial
comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or
without cisplatin.
SO - Eur J Cancer 2002 Jul;38(11):1501-11
AD - Medizinische Klinik III, UKBF, Free University Berlin, Hindenburgdamm
30, 12200, Berlin, Germany. keilholz@ukbf.fu-berlin.de
The aim of this study was to define prognostic factors for survival, and
especially for long-term survival in a mature data-set of patients with
stage IV melanoma treated within a randomised trial of cytokine-based
protocols. Long-term follow-up data on patients enrolled into a European
Organization for Research and Treatment of Cancer (EORTC) trial
comparing interferon-alpha (IFNalpha) plus interleukin-2 (IL-2) with or
without cisplatin were collected. Univariate and multivariate Cox
regression analyses were performed to define prognostic factors for
survival. The characteristics of patients alive at 2 and 5 years after
randomisation were compared with the entire cohort using the chi(2)
test. The minimum potential follow-up of the 131 evaluable patients was
5 years. 18 patients (14%) were alive 2 years after randomisation, and
11 (8%) 5 years after randomisation. Pretreatment performance status
(PS), serum lactate dehydrogenase (LDH) and tumour mass were significant
predictors for survival, whereas site of metastases and number of sites
were non-significant. PS and LDH were the only independent prognostic
factors. All except 1 patient alive at 2 and 5 years had a pretreatment
PS of 100%, and only three long-term survivors had elevated pretreatment
LDH. There was no association between the site of metastases and
long-term survival. Response to treatment was a major predictor for
long-term survival, whereas addition of cisplatin did not impact upon
overall survival probability or on long-term survival. The probability
of long-term survival in stage IV melanoma patients after IL-2-based
treatments is governed by pretreatment PS, serum LDH and response to
treatment. Site of metastases, the basis for the M-subcategories of the
new AJCC staging system, was not informative in this study.
21
UI - 8262738
AU - Quan WD Jr; Mitchell MS
TI -
Phase II trial of carbetimer in metastatic melanoma.
SO - Invest New Drugs 1993 May-Aug;11(2-3):231-3
AD - USC/Norris Comprehensive Cancer Center, Los Angeles.
A phase II study of the synthetic polyelectrolyte Carbetimer 6500 mg/m2
i.v. daily for five days every 21-day cycle was conducted in patients
with metastatic melanoma. No responses were seen in 18 evaluable
patients. Two patients had stable disease for five months. Toxicity was
generally manageable and included mild hyperphosphatemia, mild
proteinuria, fatigue, pain at the injection site, and nausea. Carbetimer
is inactive in metastatic melanoma at this dose and schedule.
22
UI - 9932599
AU - Myers JN
TI -
Value of neck dissection in the treatment of patients with
intermediate-thickness cutaneous malignant melanoma of the head and
neck.
SO - Arch Otolaryngol Head Neck Surg 1999 Jan;125(1):110-5
AD - Department of Surgery, University of Texas M. D. Anderson Cancer Center,
Houston 77030, USA. jmyers@notes.mdacc.tmc.edu
23
UI - 9932601
AU - Fisher SR
TI -
Considerations in the surgical treatment of malignant melanoma.
SO - Arch Otolaryngol Head Neck Surg 1999 Jan;125(1):116-7
24
UI - 12100184
AU - McKenna DB; Lee RJ; Prescott RJ; Doherty VR
TI -
The time from diagnostic excision biopsy to wide local excision for
primary cutaneous malignant melanoma may not affect patient survival.
SO - Br J Dermatol 2002 Jul;147(1):48-54
AD - Department of Dermatology, Royal Infirmary of Edinburgh, Scotland, UK.
dermotbmckenna@hotmail.com
BACKGROUND: The surgical management of primary cutaneous malignant
melanoma usually involves an excision biopsy of the suspected lesion
followed by wide local excision. No study has addressed whether a delay
between these two surgical procedures influences patient outcome.
OBJECTIVES: To determine if the surgical interval (SI) between the
diagnostic excision biopsy and wide local excision for primary cutaneous
malignant melanoma affects recurrence or survival outcome. METHODS: A
cohort of 986 patients who had a diagnostic excision biopsy followed by
wide local excision was identified from those registered on a specialist
database that records the clinicopathological features, surgical
treatment and follow-up information of all patients with malignant
melanoma in Scotland. The cohort was divided into five arbitrary groups
determined by the length of the SI as follows:< or =14 days, 15-28 days,
29-42 days, 43-91 days and > or = 92 days. Overall survival,
disease-free survival and recurrence-free interval between the groups
were compared univariately and multivariately. RESULTS: The mean age at
excision biopsy was 47.4 years and the median period of follow-up was 5
years (range 27 days to 20.7 years). The median SI was 30 days (range
1-468 days). The SI was: (i)< or =14 days for 130 (13%); (ii) 15-28 days
for 320 (33%); (iii) 29-42 days for 262 (27%); (iv) 43-91 days for 251
(25%); and (v) > or = 92 days for 23 (2%) patients. The latter group was
older, had thinner melanomas, a higher percentage of lesions on the head
and neck, fewer superficial spreading malignant melanomas and ulceration
present less often compared with patients treated earlier. Univariately,
there was no significant difference in overall survival (P = 0.60) or
disease-free survival (P = 0.24) between the groups. Although there was
a statistically significant difference in the percentage of
recurrence-free patients between the groups (P = 0.011), the better
recurrence-free rates occurred in the 29-42 and 43-91 day groups. After
adjusting for age, sex, tumour thickness, site, histology, ulceration
and mitotic activity using Cox's proportional hazards model, there was
no statistically significant difference in overall survival,
disease-free survival and recurrence-free percentages between the
surgical groups (P = 0.88, P = 0.44 and P = 0.084, respectively).
CONCLUSIONS: There was no evidence that survival outcome or recurrence
was related to the time interval between the diagnostic excision biopsy
and wide local excision of melanoma.
25
UI - 12169366
AU - Dresel A; Kuhn JA; McCarty TM
TI -
Sentinel node biopsy site used as full thickness skin graft donor for
cutaneous melanoma.
SO - Am J Surg 2002 Aug;184(2):176-8
AD - Baylor University Medical Center, Department of Surgery, Dallas, TX
75246, USA.
BACKGROUND: Wound defects after wide local excision (WLE) for cutaneous
melanoma can occasionally require the use of skin grafts for closure.
Harvesting the skin graft can result in an additional wound. METHODS:
The increasing use of sentinel lymph node (SLN) biopsy in cutaneous
melanoma at our institution has facilitated the development of an
alternative technique for obtaining donor skin. The proposed method
utilizes the skin overlying the SLN as the skin graft donor site.
Sixteen patients underwent WLE of intermediate to thick melanomas with
SLN biopsy and full thickness skin graft harvested from the SLN biopsy
site. RESULTS: After a median follow-up of 12 months, there were no
graft failures. There were 2 partial graft losses. There were no wound
complications. There were no melanoma recurrences. CONCLUSIONS: In cases
where primary closure is not technically feasible or cosmetically
favorable, the use of the SLN incision site as a skin graft donor
provides the surgeon with an effective repair and spares the patient an
additional skin graft donor site defect.
26
UI - 12209697
AU - Kirkwood JM; Richards T; Zarour HM; Sosman J; Ernstoff M; Whiteside TL;
TI -
Ibrahim J; Blum R; Wieand S; Mascari R
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in
patients with high-risk resected melanoma: the E2690 laboratory
corollary of intergroup adjuvant trial E1690.
SO - Cancer 2002 Sep 1;95(5):1101-12
AD - Department of Medicine, University of Pittsburgh, Pennsylvania, USA.
jmk@jimmy.harvard.edu
BACKGROUND: The clinical antitumor activity of recombinant interferon
alpha2b (IFNalpha2b) has been well documented in patients with advanced
and high-risk melanoma; however, its mechanism of action remains
conjectural. Trial E2690 evaluated the immunomodulatory effects of
IFNalpha2b in vivo during treatment at high doses (the HDI arm; n = 51
patients) and at low doses (the LDI arm; n = 54 patients) in relation to
standard observation (OBS; n = 43 patients). METHODS: This study
evaluated peripheral blood lymphocytes (PBLs) for phenotypic markers and
cytotoxic functions at 1 month, 3 months, and 12 months in the HDI arm,
the LDI arm, and the OBS arm and examined correlations between changes
observed in PBLs or in tumors with regard to treatment dosage and
disease outcome. Tumor biopsy samples were studied for response to
IFNalpha2b at a range of concentrations in vitro. RESULTS: Baseline
blood phenotypic and functional assays did not predict disease outcome;
however, modulation of these immunologic assays by IFNalpha2b treatment
was observed and was associated with IFNalpha2b dosage. Tumor cell class
II major histocompatibility antigen expression (human
leukocyte/lymphocyte antigen DR) and adhesion molecule expression
(ICAM-1) were modulated by exposure to IFNalpha2b in a dose dependent
manner. Blood natural killer (NK) cell function, T-cell function, and
subset distribution were modulated early by patients in the HDI arm and
later by patients in the LDI arm. None of the variables tested in these
studies predicted recurrence free survival. The numbers of patients
studied were smaller than may be needed to detect potentially clinically
significant changes. CONCLUSIONS: These data demonstrate changes in
immunologic parameters associated with IFNalpha2b treatment and dosage
that may account for some of the differences in the clinical efficacy of
this modality. The current results also suggest the need for further
study of newer molecular intermediates of IFNalpha2b and T-cell response
to specific antigens of melanoma. Copyright 2002 American Cancer
Society.
27
UI - 12209676
AU - Sondak VK
TI -
How does interferon work? Does it even matter?
SO - Cancer 2002 Sep 1;95(5):947-9
28
UI - 9506534
AU - Molinari A; Calcabrini A; Meschini S; Stringaro A; Del Bufalo D;
TI -
Cianfriglia M; Arancia G
Detection of P-glycoprotein in the Golgi apparatus of drug-untreated
human melanoma cells.
SO - Int J Cancer 1998 Mar 16;75(6):885-93
AD - Laboratorio di Ultrastrutture, Istituto Superiore di Sanita, Rome,
Italy.
The intracellular location of the MDR1 gene product, known as
P-glycoprotein (P-gp), has been detected by flow cytometry in 3
stabilized human melanoma cell lines which had never undergone cytotoxic
drug treatment and did not express P-gp on the plasma membrane. In
addition, MDR1 mRNA expression was revealed by RT-PCR in the same cell
lines. Immunofluorescence microscopy, performed by using the same 2
monoclonal antibodies (MM4.17 and MRK-16) as employed in the
flow-cytometric analysis, revealed the presence of P-gp
intracytoplasmically, in a well-defined perinuclear region. Double
immunofluorescence labelling and immunoelectron microscopy strongly
suggested the location of the transporter molecule in the Golgi
apparatus. The same observations have been obtained on a primary culture
from a metastasis of human melanoma. Analysis of the expression of
another membrane transport protein, the multidrug-resistance-related
protein (MRP1), showed that it was present in the cytoplasm of all the
melanoma cell lines examined. MRP1 also showed Golgi-like localization.
The study by laser scanning confocal microscopy on the intracellular
localization of the anti-tumoral agent doxorubicin (DOX) during the
drug-uptake and -efflux phases, indicated the Golgi apparatus as a
preferential accumulation site for the anthracyclinic antibiotic. P-gp
function modulators (verapamil and cyclosporin A) were able to modify
DOX intracytoplasmic distribution and to increase drug intracellular
concentration and cytotoxic effect in melanoma cells. On the contrary,
MRP1 modulators (probenecid and genistein) did not significantly
influence either DOX efflux and distribution or the sensitivity of
melanoma cells to the cytotoxic drug.
29
UI - 12202672
AU - Kirkwood JM; Bender C; Agarwala S; Tarhini A; Shipe-Spotloe J; Smelko B;
TI -
Donnelly S; Stover L
Mechanisms and management of toxicities associated with high-dose
interferon alfa-2b therapy.
SO - J Clin Oncol 2002 Sep 1;20(17):3703-18
AD - University of Pittsburgh Cancer Institute, University of Pittsburgh
School of Medicine, Pittsburgh, PA 15213, USA. jmk@jimmy.harvard.edu
PURPOSE: The toxicity associated with adjuvant high-dose
interferon-alfa-2b therapy (HDI) for high-risk melanoma can lead to
premature discontinuation. It is important to understand the expected
adverse events and their underlying mechanisms and to anticipate and
aggressively manage toxicity during treatment in order to ensure that
patients receive the maximum therapeutic benefit. METHODS: The toxicity
profile of HDI was reviewed by examining data from the United States
cooperative group trials. Available published data related to the
potential mechanisms responsible for the observed adverse events are
discussed, and comprehensive recommendations for managing side effects
are presented. RESULTS: The HDI regimen is associated with acute
constitutional symptoms, chronic fatigue, myelosuppression, elevated
liver enzyme levels, and neurologic symptoms. The majority of patients
tolerate 1 year of therapy with an understanding of the anticipated
toxicities in conjunction with appropriate dose modifications and
supportive care. Ongoing monitoring for liver dysfunction and
hematologic toxicity is critical to ensure safety. Many of the
toxicities associated with interferon-alfa (IFN-alpha) seem to be the
result of endogenous cytokines and their effects on the neuroendocrine
system. Recent data have also demonstrated that IFN-alpha suppresses the
activity of specific CYP450 isoenzymes and that this correlates with
discrete toxicities. Pharmacologic interventions are under study for
fatigue and depression. An increased understanding of the mechanisms of
IFN-alpha-associated toxicity will lead to more rational and effective
supportive care and improved quality of life. CONCLUSION: Continued
research in this area should lead to improvements in the safety and
tolerability of adjuvant therapy for melanoma.
30
UI - 12028515
AU - Harvie MN; Campbell IT; Howell A; Thatcher N
TI -
Acceptability and tolerance of a low tyrosine and phenylalanine diet in
patients with advanced cancer -- a pilot study.
SO - J Hum Nutr Diet 2002 Jun;15(3):193-202
AD - University Department of Medical Oncology, South Manchester University
Hospitals NHS Trust, Manchester, UK. m_harvie@fs1.with.man.ac.uk
BACKGROUND: Low phenylalanine (phe) and tyrosine (tyr) diets limit
tumour growth in animal models and may offer a novel cancer therapy. We
studied the efficacy and acceptability of a low phe and tyr diet in
patients with advanced cancer. METHODS: Patients with advanced
metastatic melanoma (n=22) and metastatic breast cancer (n=15) were
invited to follow a low phe and tyr diet (10 mg kg-1 phe and tyr per
day) for 1 month. In those individuals who followed the diet for 1
month, we attempted to establish the effects on nutritional status (body
weight, fat free mass, percentage body fat, serum albumin), immune cell
function (white cell count, lymphocytes and neutrophils), plasma levels
of phe-tyr and tryptophan and quality of life (Hospital Anxiety and
Depression score). RESULTS: Only three of the 22 patients with
metastatic melanoma and three of the 15 patients with metastatic breast
cancer agreed to start the diet. All patients experienced problems and
side-effects and increases in anxiety and depression. There were
declines in weight, with loss of fat and fat free mass but slight
increases in white cell counts and neutrophils. CONCLUSIONS: Low phe and
tyr diets do not appear to be a viable treatment option for patients
with advanced cancer.
31
UI - 12107949
AU - Lorentzen HF; Weismann K
TI -
[The shadow rule and appropriate sun behavior]
SO - Ugeskr Laeger 2002 Jun 17;164(25):3346-50
AD - Dermatologisk afdeling D42, H:S Bispebjerg Hospitalet, DK-2400 Kobenhavn
NV.
INTRODUCTION: Sun lotions have not been effective in preventing the
alarming increase in the incidence of melanoma, possibly, because of
incorrect use, lack of protection from UVA and increased exposure times
caused by reduced penetration of erythemogenic UVB. Seeking shade
prevents deleterious effects from the sun's ultraviolet rays. MATERIAL
AND METHODS: We examined the association between UV intensity and the
ratio of shadow length to object height. A linear model fitted the data
(R = 0.95). With an astronomical navigation equation for the calculation
of altitude of the sun and substituting altitude with UV intensity we
developed a model predicting the UV load from the point of observation,
the time of the year (declination) and the time of day (hour angle).
Accumulated UV doses can be calculated by integration. RESULTS: When the
shadow to object ratio is 0.5, skin types I and II will experience
erythema after a few minutes, when the ratio is 1 erythema appears after
20-30 minutes, and when the ratio is 2 erythema appears after about one
hour. In the Mediterranean, accumulated UV exposure from sunrise to
sunset in late summer will be 30-50 times the minimal erythema dose
(skin types I + II) of which more than 60% is in the interval where the
shadow is shorter than its object. DISCUSSION: The shadow rule (short
shadows--seek shade) is simple and universal and children can be taught
it. A rule of thumb is: when shadows are shorter than objects throwing
them, avoid direct sunlight, when shadow and object are of equal length
restrict sun exposure to half an hour, and when shadows are twice the
length of objects an hour in the sun is permissible.
32
UI - 12143158
AU - Sales F; Bourgeois P; Verdebout JM
TI -
[Role of sentinel node biopsy in the management of melanoma]
SO - Rev Med Brux 2002 Jun;23(3):A176-9
AD - Service de Chirurgie, Institut J. Bordet, U.L.B.
33
UI - 11757453
AU - Hauschild A; Eiling S; Lischner S; Haacke TC; Christophers E
TI -
[Safety margins in the excision of primary malignant melanoma. Proposals
based on controlled clinical trials]
SO - Hautarzt 2001 Nov;52(11):1003-10
AD - Universitats-Hautklinik Kiel. ahauschild@dermatology.uni-kiel.de
Excisional biopsy is recommended as the procedure of choice whenever
there is suspicion of malignant melanoma. Incisional biopsies are only
rarely indicated. For nearly seventy years the debate about the optimum
resection safety margin around the primary tumor was influenced by
historical case reports and paradigms. Recently, controlled clinical
studies have provided new insights. Accumulating evidence over the last
two decades shows that narrower surgical margins influence neither the
rate of satellites or in-transit-metastases nor the occurrence of
advanced metastatic disease. Local recurrence is rare (approx. 0.1%)
when primary tumors are thin and is seen more often (approx. 10%) in
primary tumors of greater thickness (> 4 mm). Analysis of the overall
survival in randomized trials shows equal prognosis for malignant
melanoma for narrow and wide resection margins. Due to these findings
in-toto excisional biopsy for in-situ melanoma, a resection margin of 1
cm for thin primary tumors (< 1 cm tumor thickness) and a resection
margin of 1 to 2 cm for primary tumors greater than 1 mm appears
sufficient. With these recommendations, primary closure of wounds will
be possible in nearly all cases, reducing surgical costs and morbidity.
This article should serve as a basis of discussion for the proposed
revision of the current guidelines of the German Dermatologic Society
(DDG) on the primary surgical care of melanoma patients.
34
UI - 12053699
AU - Mohrle M; Breuninger H
TI -
[Comment on the contribution by A. Hauschild et al.: "Safety margins in
excision of primary malignant melanoma"]
SO - Hautarzt 2002 Apr;53(4):291-2
35
UI - 12133625
AU - Housseau F; Lindsey KR; Oberholtzer SD; Gonzales MI; Boutin P; Moorthy
TI -
AK; Shankara S; Roberts BL; Topalian SL
Quantitative real-time RT-PCR as a method for monitoring T lymphocyte
reactivity to full
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
